Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels. Yet drug concentrations and TDM are not commonplace in many places - time for change Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc

• https://x.com/drdavidliew/status/1983555247269404896/photo/1

Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice Comments on Abstract #1415 presented at #ACR25 https://t.co/GilOFvXajJ @RheumNow

• The Upper Hand in PsA? Not the Dominant One | RheumNow

Year in Preview GCA: GC over-prescribed, bDMARDs more effective than MTX, and more options available (TOC, JAKi) @RheumNow #ACR25 https://t.co/L9fx1LCCnw

• https://x.com/JihaRheum/status/1983554568974909545/photo/1
• https://x.com/JihaRheum/status/1983554568974909545/photo/1
• https://x.com/JihaRheum/status/1983554568974909545/photo/1

Click on the link to see my take on implantable vagal nerve stimulation RCT in RA 🎥👇🏼 https://t.co/CZrFKouSqp @RheumNow #ACR25 #ABSTRACT1675

• Wired for Success: Vagal Nerve Therapy in RA | RheumNow

“We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review She told us she is speaking about diseases outside her comfort zone but she is bang on. As she said: not good enough real world all the people not on steroid-sparing Rx @RheumNow https://t.co/4WiEORwPgI

• https://x.com/drdavidliew/status/1983554079453483409/photo/1

#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1
• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1

Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

• https://x.com/AurelieRheumo/status/1983553385505726631/photo/1

Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

• https://x.com/JihaRheum/status/1983553108535136270/photo/1

Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

• https://x.com/AurelieRheumo/status/1983552472221163564/photo/1

ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

• https://x.com/JihaRheum/status/1983551740202095038/photo/1

#YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd

• https://x.com/DrMiniDey/status/1983551437800923182/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.